Insider Cluster (3 insiders) ·Filed Apr 15, 2026

BCAX

Bicara Therapeutics Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed5mo ago
Insider cluster: 3 insiders, $0.7M total
Actionable Insight • Neutral

Monitor upcoming 10-Q filing for any changes in revenue or cash runway; while these sales are modest relative to market cap and likely part of pre-arranged 10b5-1 plans, the concentration among top leadership warrants attention for follow-on signals.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
BCAX ▲ +21.88% at T+60d
NEUTRAL call ✓ call won +21.88% · α vs SPY +13.74% · entry $23.72 → $28.91
Entry anchored
Apr 14, 03:59 PM ET
via exchange tick
T+1d
+0.89%
call +0.89% · α +0.63%
$23.93
settled 6mo ago
T+5d
-0.38%
call -0.38% · α -2.02%
$23.63
settled 5mo ago
T+20d
-5.65%
call -5.65% · α -11.69%
$22.38
settled 5mo ago
T+60d
+21.88%
call +21.88% · α +13.74%
$28.91
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Three top executives at Bicara Therapeutics — including the CEO, CFO, and President/COO — collectively sold $750K worth of shares in open-market transactions over a 7-day period. These sales coincide with recent option exercises, suggesting planned equity monetization rather than reactive selling.

Key Financial Metrics

Direction
selling
Total Value
$750.0K
Insiders
3

Key Facts

  • CEO Mazumdar Claire sold $354K of shares, following option exercises totaling over $93K in value.
  • CFO Hyep Ivan sold $212K of shares, preceded by derivative exercises worth $34.9K.
  • President and COO Cohlhepp Ryan sold $184K of shares on April 15.
  • Total insider sales: $750K over 7 days, representing 0.05% of the company's $1.5B market cap.
  • All sales were open-market (code S), with no issuer-directed or forced transactions.

Financial Impact

$750,000 in total open-market sales by three C-suite executives

insider ownershipmarket sentiment

Risk Factors

  • Perception of lack of confidence if no formal plan disclosure is provided
  • Potential for negative market reaction if similar selling continues in next quarter

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-BCAX-1776891240914
20 reports for BCAX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for BCAX — sortable, filterable
TypeNow
Aug 25, 2026
5w ago
8-K
NEUTRAL ★ 2/10
$24.73 $19.78▼ −20.02%▼ −20.24%$18.25 (−26.18%)
Aug 14, 2026
7w ago
Press Release
NEUTRAL ★ 2/10
$24.28 $23.20▼ −4.45%▼ −2.46%$18.25 (−24.81%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 5/10
$23.63 $22.81▼ −3.47%▼ −1.72%$18.25 (−22.75%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 4/10
$23.63 $22.81▼ −3.47%▼ −1.72%$18.25 (−22.75%)
Aug 11, 2026
7w ago
8-K
MIXED ★ 6/10
$23.76 $23.64▼ −0.51%▲ +0.55%$18.25 (−23.17%)
Aug 11, 2026
7w ago
Press Release
MIXED ★ 6/10
$23.76 $23.64▼ −0.51%▲ +0.55%$18.25 (−23.17%)
Jul 14, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$28.10 $23.76▼ −15.44%▼ −17.94%$18.25 (−35.04%)
Jun 11, 2026
16w ago
Institutional Cluster
BEARISH ★ 5/10
$21.28 $29.68▼ −39.47%▼ −37.58%$18.25 (+14.22%)
May 26, 2026
18w ago
Insider Cluster
NEUTRAL ★ 2/10
$21.58 $26.34▲ +22.06%▲ +23.96%$18.25 (−15.41%)
May 11, 2026
20w ago
8-K
NEUTRAL ★ 4/10
$22.92 $20.56▼ −10.30%▼ −9.99%$18.25 (−20.35%)
Showing 10 of 20

US Market Status

Market Open — Closes in 3h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 22, 2026